Literature DB >> 23021767

Rapid decrease in forced vital capacity in patients with idiopathic pulmonary upper lobe fibrosis.

Kentaro Watanabe1, Nobuhiko Nagata, Yasuhiko Kitasato, Kentaro Wakamatsu, Kazuki Nabeshima, Taishi Harada, Takako Hirota, Motokimi Shiraishi, Masaki Fujita.   

Abstract

BACKGROUND: We are occasionally presented with patients with unclassifiable interstitial pneumonia of unknown etiology. Idiopathic pulmonary upper lobe fibrosis (IPUF) does not fit any of the currently defined subsets of idiopathic interstitial pneumonias (IIPs). This study was performed to examine clinical, functional, and pathological characteristics of IPUF.
METHODS: We present 9 cases of histologically confirmed IPUF. The clinical and histological characteristics of the 9 patients were evaluated. The baseline respiratory function of all patients was measured. There were 7 patients whose forced vital capacity (FVC) had been monitored for at least a year who were selected to quantify the yearly decline in FVC.
RESULTS: All patients were slender, with a body mass index of 16.0-19.8 kg/m(2). Seven patients had a history of pneumothorax. Six patients died 1.8 to 5.7 years after the onset of the first symptoms. Fundamental histological features were intraalveolar collagen deposition and densely packed elastic fibers in the subpleural areas. These findings are the same as those seen in pleuroparenchymal fibroelastosis. However, the visceral pleura was thickened with dense collagen in only 2 patients, and pleural thickening was localized, if present, in the remaining 7 patients. Ventilatory impairment was also a characteristic. The time course decline of FVC was rapid and almost linear. The median yearly decline in FVC was -20.3% (range, -7.7% to -26.5%), which was more rapid than that reported for chronic fibrosing interstitial pneumonias such as idiopathic pulmonary fibrosis.
CONCLUSIONS: IPUF is a unique pulmonary fibrosis that results in rapid deterioration of ventilatory function and poor prognosis.
Copyright © 2012 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23021767     DOI: 10.1016/j.resinv.2012.06.003

Source DB:  PubMed          Journal:  Respir Investig        ISSN: 2212-5345


  28 in total

Review 1.  [Interstitial lung diseases. The pattern is important].

Authors:  L Fink
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

2.  Body Mass Index and arterial blood oxygenation as prognostic factors in patients with idiopathic pleuroparenchymal fibroelastosis.

Authors:  Hiroki Hayashi; Takahito Nei; Shinji Abe; Yoshinobu Saito; Nariaki Kokuho; Kenichiro Atsumi; Kazue Fujita; Takefumi Saito; Takahiro Tanaka; Akihiko Gemma; Arata Azuma
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

Review 3.  Biofabrication of phenotypic pulmonary fibrosis assays.

Authors:  Cameron Yamanishi; Stephen Robinson; Shuichi Takayama
Journal:  Biofabrication       Date:  2019-06-19       Impact factor: 9.954

Review 4.  Pleuroparenchymal fibroelastosis (PPFE) treated with lung transplantation and review of the literature.

Authors:  Muhammad Sajawal Ali; Vijaya Sivalingam Ramalingam; George Haasler; Kenneth Presberg
Journal:  BMJ Case Rep       Date:  2019-04-20

5.  Pleuroparenchymal fibroelastosis: the prevalence of secondary forms in hematopoietic stem cell and lung transplantation recipients.

Authors:  Francesca Mariani; Beatrice Gatti; Alberto Rocca; Francesca Bonifazi; Alberto Cavazza; Stefano Fanti; Sara Tomassetti; Sara Piciucchi; Venerino Poletti; Maurizio Zompatori
Journal:  Diagn Interv Radiol       Date:  2016 Sep-Oct       Impact factor: 2.630

6.  An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.

Authors:  William D Travis; Ulrich Costabel; David M Hansell; Talmadge E King; David A Lynch; Andrew G Nicholson; Christopher J Ryerson; Jay H Ryu; Moisés Selman; Athol U Wells; Jurgen Behr; Demosthenes Bouros; Kevin K Brown; Thomas V Colby; Harold R Collard; Carlos Robalo Cordeiro; Vincent Cottin; Bruno Crestani; Marjolein Drent; Rosalind F Dudden; Jim Egan; Kevin Flaherty; Cory Hogaboam; Yoshikazu Inoue; Takeshi Johkoh; Dong Soon Kim; Masanori Kitaichi; James Loyd; Fernando J Martinez; Jeffrey Myers; Shandra Protzko; Ganesh Raghu; Luca Richeldi; Nicola Sverzellati; Jeffrey Swigris; Dominique Valeyre
Journal:  Am J Respir Crit Care Med       Date:  2013-09-15       Impact factor: 21.405

7.  Idiopathic pleuroparenchymal fibroelastosis is characterized by an elevated serum level of surfactant protein-D, but Not Krebs von den Lungen-6.

Authors:  Seidai Sato; Masaki Hanibuchi; Asami Fukuya; Youhei Yabuki; Hiroki Bando; Terumi Yoshijima; Hisatsugu Goto; Hirohisa Ogawa; Yasuhiko Nishioka
Journal:  Lung       Date:  2014-06-01       Impact factor: 2.584

Review 8.  The pathogenesis and pathology of idiopathic pleuroparenchymal fibroelastosis.

Authors:  Yoshiaki Kinoshita; Hiroshi Ishii; Kazuki Nabeshima; Kentato Watanabe
Journal:  Histol Histopathol       Date:  2020-12-14       Impact factor: 2.303

9.  Histological evolution of pleuroparenchymal fibroelastosis.

Authors:  Takako Hirota; Yuji Yoshida; Yasuhiko Kitasato; Michihiro Yoshimi; Takaomi Koga; Nobuko Tsuruta; Masato Minami; Taishi Harada; Hiroshi Ishii; Masaki Fujita; Kazuki Nabeshima; Nobuhiko Nagata; Kentaro Watanabe
Journal:  Histopathology       Date:  2014-12-23       Impact factor: 5.087

10.  Pleuroparenchymal fibroelastosis: a rare interstitial lung disease.

Authors:  John C English; John R Mayo; Robert Levy; John Yee; Kevin O Leslie
Journal:  Respirol Case Rep       Date:  2015-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.